For a while now, Bayer and Johnson & Johnson's Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.
We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.
India may soon make scuttlebutt on medical device price controls a reality, starting with orthopedic implants, the Times of India reports, as the National Pharmaceutical Pricing Authority asks Johnson & Johnson, Zimmer and Stryker to submit details of production and pricing of their products, including those for knee and hip.
FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.
At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.
Flat news is good news. Pharma spending on advertising and promotional expenses will dip by just 1.7% next year, according to Schonfeld & Associates' annual Advertising Ratios & Budgets. That means a total of more than $21 billion in ad spending and just a bit healthier than last year's decline of 2%.
The race for an Ebola vaccine has slowed to a crawl as Big Pharmas GlaxoSmithKline, Merck and Johnson & Johnson struggle to find volunteers who are exposed to enough disease to show whether experimental vaccines actually protect against Ebola infection.
Johnson & Johnson is expanding its medical device manufacturing in Ireland, sinking €100 million ($112 million) into its site in Limerick and opening a €53 million ($59 million) plant in Cork as it looks to chart some upward momentum for its lagging device business.
Back in November, the FDA gave drugmakers producing cheap knockoffs of Johnson & Johnson's ADHD med Concerta 6 months to prove that their copycat versions were equivalent to the brand-name drug, or remove their product from the market. But that time has come and gone, and the FDA has yet to issue a final word on the meds.
Another week, another rumor about the target on GlaxoSmithKline's back. This time, U.K. traders were talking up a different potential takeover--not by Pfizer, but by Johnson & Johnson or Roche.